Abstract
Nine trials qualified for this limited review of antiplatelet drugs used in secondary prevention of myocardial infarction. The criterion for inclusion was a placebo-controlled, randomized trial with a sample size of at least 100 (May et al. 1982). Six of these trials involved asprin alone, one aspirin plus Persantin (dipyridimole), and two Anturan (sulfinpyrazone).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anturane Reinfarction Italian Study (1982) Sulphinpyrazone in post-myocardial infarction. Lancet 1: 237–242
The Anturan Reinfarction Trial Research Group (1978) Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. N Engl. J Med 298: 289–295
The Anturan Reinfarction Trial Research Group (1980) Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 302: 250–256
Aspirin Myocardial Infarction Study Research Group (1980) A randomized controlled trial of persons recovered from myocardial infarction. JAMA 243: 661
Breddin K, Loew D, Lechner K, Uberla K, Walter E (1979) Secondary prevention of myocardial infarction. Comparison of acetylsalicylic acid, phenprocoumon and placebo. A multi-center two-year prospective study. Thromb Haemost 40: 225
Canner PL (1982) Aspirin in coronary heart disease: comparison of six clinical trials. Presented at the fourth international symposium of clinical trials (Beer-Sheva, January 1982) Isr J Med Sci 5: 1983
The Coronary Drug Project Research Group (1976) Aspirin in coronary heart disease. J Chron Dis 29: 625
Elwood PC, Sweetnam PM (1979) Aspirin and secondary mortality after myocardial infarction. Lancet 2: 1313
Elwood PC, Cochrane Al, Bur ML, Sweetnam PM, Williams G, Welsby E, Hughes SJ, Renton R (1974) A randomized controlled trial of acetylaslicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J 1: 436
The EPSIM Research Group (1982) A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 307: 701–708
FDA Drug Bulletin (1978) Sulfinpyrazone and prevention of myocardial infarction, May–July 1978, pp 19–20
Fleiss JL (1973) Statistical methods for rates and proportions. Wiley, New York, pp 115–117
Boston Collaborative Drug Surveillance Group (1974) Regular aspirin intake and acute myocardial infarction. Med J 1: 440
May GS, Eberlein KA, Furberg CD, et al. (1982) Secondary prevention after myocardial infarction: a review of long-term trials. Prog Cardiovasc Dis 24: 349
The Persantin-Aspirin Reinfarction Trial Research Group (1980) Persantine and aspirin in coronary heart disease. Circulation 62: 449
Peto R (1980) Editorial: Aspirin after myocardial infarction. Lancet 1: 1172–1173
Temple R, Pledger GW (1980) The FDA’s critique of the anturan reinfarction trial. N Engl J Med 303: 1488–1492
Woolf B (1955) On estimating the relation between blood group and disease. Ann Hum Genet 19: 251–253
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Spriger-Verlag Berlin Heidelberg
About this paper
Cite this paper
Klimt, C.R., Forman, S.A. (1983). Secondary Prevention of Myocardial Infarction with Antiplatelet Drugs. In: Roskamm, H. (eds) Prognosis of Coronary Heart Disease Progression of Coronary Arteriosclerosis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-69052-5_25
Download citation
DOI: https://doi.org/10.1007/978-3-642-69052-5_25
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-69054-9
Online ISBN: 978-3-642-69052-5
eBook Packages: Springer Book Archive